In this report, the EMEA Benign Prostatic Hyperplasia (BPH) Drugs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (MT), revenue (Million USD), market share and growth rate of Benign Prostatic Hyperplasia (BPH) Drugs for these regions, from 2012 to 2022 (forecast)
Europe: Germany, France, UK, Russia, Italy and Benelux;
Middle East: Saudi Arabia, Israel, UAE and Iran;
Africa: South Africa, Nigeria, Egypt and Algeria.

EMEA Benign Prostatic Hyperplasia (BPH) Drugs market competition by top manufacturers/players, with Benign Prostatic Hyperplasia (BPH) Drugs sales volume (MT), price (USD/Kg), revenue (Million USD) and market share for each manufacturer/player; the top players including
Astellas Pharma
Eli Lilly
GlaxoSmithKline
Sanofi
ADC Therapeutics
Advaxis
Agennix
ANI Pharmaceuticals
BHR Pharma
Bristol-Myers Squibb
Boehringer Ingelheim
Dendreo
Endo Pharmaceuticals

On the basis of product, this report displays the sales volume (MT), revenue (Million USD), product price (USD/Kg), market share and growth rate of each type, primarily split into
Alpha-blocker
Phosphodiesterase type-5 inhibitors
5-alpha-Reductase inhibitors

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume (MT), market share and growth rate of Benign Prostatic Hyperplasia (BPH) Drugs for each application, including
Clinical medicine
Scientific research
Others

Table of Contents

EMEA (Europe, Middle East and Africa) Benign Prostatic Hyperplasia (BPH) Drugs Market Report 2017
1 Benign Prostatic Hyperplasia (BPH) Drugs Overview
1.1 Product Overview and Scope of Benign Prostatic Hyperplasia (BPH) Drugs
1.2 Classification of Benign Prostatic Hyperplasia (BPH) Drugs
1.2.1 EMEA Benign Prostatic Hyperplasia (BPH) Drugs Market Size (Sales) Comparison by Type (2012-2022)
1.2.2 EMEA Benign Prostatic Hyperplasia (BPH) Drugs Market Size (Sales) Market Share by Type (Product Category) in 2016
1.2.3 Alpha-blocker
1.2.4 Phosphodiesterase type-5 inhibitors
1.2.5 5-alpha-Reductase inhibitors
1.3 EMEA Benign Prostatic Hyperplasia (BPH) Drugs Market by Application/End Users
1.3.1 EMEA Benign Prostatic Hyperplasia (BPH) Drugs Sales (Volume) and Market Share Comparison by Application (2012-2022
1.3.2 Clinical medicine
1.3.3 Scientific research
1.3.4 Others
1.4 EMEA Benign Prostatic Hyperplasia (BPH) Drugs Market by Region
1.4.1 EMEA Benign Prostatic Hyperplasia (BPH) Drugs Market Size (Value) Comparison by Region (2012-2022)
1.4.2 Europe Status and Prospect (2012-2022)
1.4.3 Middle East Status and Prospect (2012-2022)
1.4.4 Africa Status and Prospect (2012-2022)
1.5 EMEA Market Size (Value and Volume) of Benign Prostatic Hyperplasia (BPH) Drugs (2012-2022)
1.5.1 EMEA Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2012-2022)
1.5.2 EMEA Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Growth Rate (2012-2022)

2 EMEA Benign Prostatic Hyperplasia (BPH) Drugs Competition by Manufacturers/Players/Suppliers, Region, Type and Application
2.1 EMEA Benign Prostatic Hyperplasia (BPH) Drugs Market Competition by Players/Manufacturers
2.1.1 EMEA Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume and Market Share of Major Players (2012-2017)
2.1.2 EMEA Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Share by Players (2012-2017)
2.1.3 EMEA Benign Prostatic Hyperplasia (BPH) Drugs Sale Price by Players (2012-2017)
2.2 EMEA Benign Prostatic Hyperplasia (BPH) Drugs (Volume and Value) by Type/Product Category
2.2.1 EMEA Benign Prostatic Hyperplasia (BPH) Drugs Sales and Market Share by Type (2012-2017)
2.2.2 EMEA Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Market Share by Type (2012-2017)
2.2.3 EMEA Benign Prostatic Hyperplasia (BPH) Drugs Sale Price by Type (2012-2017)
2.3 EMEA Benign Prostatic Hyperplasia (BPH) Drugs (Volume) by Application
2.4 EMEA Benign Prostatic Hyperplasia (BPH) Drugs (Volume and Value) by Region
2.4.1 EMEA Benign Prostatic Hyperplasia (BPH) Drugs Sales and Market Share by Region (2012-2017)
2.4.2 EMEA Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Market Share by Region (2012-2017)
2.4.3 EMEA Benign Prostatic Hyperplasia (BPH) Drugs Sales Price by Region (2012-2017)

3 Europe Benign Prostatic Hyperplasia (BPH) Drugs (Volume, Value and Sales Price), by Players, Countries, Type and Application
3.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales and Value (2012-2017)
3.1.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume and Growth Rate (2012-2017)
3.1.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Growth Rate (2012-2017)
3.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales and Market Share by Type
3.3 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales and Market Share by Application
3.4 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume and Value (Revenue) by Countries
3.4.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume by Countries (2012-2017)
3.4.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Countries (2012-2017)
3.4.3 Germany Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2012-2017)
3.4.4 France Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2012-2017)
3.4.5 UK Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2012-2017)
3.4.6 Russia Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2012-2017)
3.4.7 Italy Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2012-2017)
3.4.8 Benelux Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2012-2017)

4 Middle East Benign Prostatic Hyperplasia (BPH) Drugs (Volume, Value and Sales Price), by Region, Type and Application
4.1 Middle East Benign Prostatic Hyperplasia (BPH) Drugs Sales and Value (2012-2017)
4.1.1 Middle East Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume and Growth Rate (2012-2017)
4.1.2 Middle East Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Growth Rate (2012-2017)
4.2 Middle East Benign Prostatic Hyperplasia (BPH) Drugs Sales and Market Share by Type
4.3 Middle East Benign Prostatic Hyperplasia (BPH) Drugs Sales and Market Share by Application
4.4 Middle East Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume and Value (Revenue) by Countries
4.4.1 Middle East Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume by Countries (2012-2017)
4.4.2 Middle East Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Countries (2012-2017)
4.4.3 Saudi Arabia Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2012-2017)
4.4.4 Israel Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2012-2017)
4.4.5 UAE Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2012-2017)
4.4.6 Iran Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2012-2017)

5 Africa Benign Prostatic Hyperplasia (BPH) Drugs (Volume, Value and Sales Price) by Players, Countries, Type and Application
5.1 Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales and Value (2012-2017)
5.1.1 Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume and Growth Rate (2012-2017)
5.1.2 Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Growth Rate (2012-2017)
5.2 Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales and Market Share by Type
5.3 Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales and Market Share by Application
5.4 Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume and Value (Revenue) by Countries
5.4.1 Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume by Countries (2012-2017)
5.4.2 Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Countries (2012-2017)
5.4.3 South Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2012-2017)
5.4.4 Nigeria Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2012-2017)
5.4.5 Egypt Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2012-2017)
5.4.6 Algeria Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate (2012-2017)

6 EMEA Benign Prostatic Hyperplasia (BPH) Drugs Manufacturers/Players Profiles and Sales Data
6.1 Astellas Pharma
6.1.1 Company Basic Information, Manufacturing Base and Competitors
6.1.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Type, Application and Specification
6.1.2.1 Product A
6.1.2.2 Product B
6.1.3 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
6.1.4 Main Business/Business Overview
6.2 Eli Lilly
6.2.1 Company Basic Information, Manufacturing Base and Competitors
6.2.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Type, Application and Specification
6.2.2.1 Product A
6.2.2.2 Product B
6.2.3 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
6.2.4 Main Business/Business Overview
6.3 GlaxoSmithKline
6.3.1 Company Basic Information, Manufacturing Base and Competitors
6.3.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Type, Application and Specification
6.3.2.1 Product A
6.3.2.2 Product B
6.3.3 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
6.3.4 Main Business/Business Overview
6.4 Sanofi
6.4.1 Company Basic Information, Manufacturing Base and Competitors
6.4.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Type, Application and Specification
6.4.2.1 Product A
6.4.2.2 Product B
6.4.3 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
6.4.4 Main Business/Business Overview
6.5 ADC Therapeutics
6.5.1 Company Basic Information, Manufacturing Base and Competitors
6.5.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Type, Application and Specification
6.5.2.1 Product A
6.5.2.2 Product B
6.5.3 ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
6.5.4 Main Business/Business Overview
6.6 Advaxis
6.6.1 Company Basic Information, Manufacturing Base and Competitors
6.6.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Type, Application and Specification
6.6.2.1 Product A
6.6.2.2 Product B
6.6.3 Advaxis Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
6.6.4 Main Business/Business Overview
6.7 Agennix
6.7.1 Company Basic Information, Manufacturing Base and Competitors
6.7.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Type, Application and Specification
6.7.2.1 Product A
6.7.2.2 Product B
6.7.3 Agennix Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
6.7.4 Main Business/Business Overview
6.8 ANI Pharmaceuticals
6.8.1 Company Basic Information, Manufacturing Base and Competitors
6.8.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Type, Application and Specification
6.8.2.1 Product A
6.8.2.2 Product B
6.8.3 ANI Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
6.8.4 Main Business/Business Overview
6.9 BHR Pharma
6.9.1 Company Basic Information, Manufacturing Base and Competitors
6.9.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Type, Application and Specification
6.9.2.1 Product A
6.9.2.2 Product B
6.9.3 BHR Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
6.9.4 Main Business/Business Overview
6.10 Bristol-Myers Squibb
6.10.1 Company Basic Information, Manufacturing Base and Competitors
6.10.2 Benign Prostatic Hyperplasia (BPH) Drugs Product Type, Application and Specification
6.10.2.1 Product A
6.10.2.2 Product B
6.10.3 Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
6.10.4 Main Business/Business Overview
6.11 Boehringer Ingelheim
6.12 Dendreo
6.13 Endo Pharmaceuticals

7 Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Cost Analysis
7.1 Benign Prostatic Hyperplasia (BPH) Drugs Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Price Trend of Key Raw Materials
7.1.3 Key Suppliers of Raw Materials
7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.2.1 Raw Materials
7.2.2 Labor Cost
7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Benign Prostatic Hyperplasia (BPH) Drugs

8 Industrial Chain, Sourcing Strategy and Downstream Buyers
8.1 Benign Prostatic Hyperplasia (BPH) Drugs Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Benign Prostatic Hyperplasia (BPH) Drugs Major Manufacturers in 2016
8.4 Downstream Buyers

9 Marketing Strategy Analysis, Distributors/Traders
9.1 Marketing Channel
9.1.1 Direct Marketing
9.1.2 Indirect Marketing
9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
9.2.1 Pricing Strategy
9.2.2 Brand Strategy
9.2.3 Target Client
9.3 Distributors/Traders List

10 Market Effect Factors Analysis
10.1 Technology Progress/Risk
10.1.1 Substitutes Threat
10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change

11 EMEA Benign Prostatic Hyperplasia (BPH) Drugs Market Forecast (2017-2022)
11.1 EMEA Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Price Forecast (2017-2022)
11.1.1 EMEA Benign Prostatic Hyperplasia (BPH) Drugs Sales and Growth Rate Forecast (2017-2022)
11.1.2 EMEA Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Growth Rate Forecast (2017-2022)
11.1.3 EMEA Benign Prostatic Hyperplasia (BPH) Drugs Price and Trend Forecast (2017-2022)
11.2 EMEA Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
11.3 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
11.4 Middle Eastt Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
11.5 Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
11.6 EMEA Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Type (2017-2022)
11.7 EMEA Benign Prostatic Hyperplasia (BPH) Drugs Sales Forecast by Application (2017-2022)

12 Research Findings and Conclusion

13 Appendix
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer




List of Tables and Figures

Figure Product Picture of Benign Prostatic Hyperplasia (BPH) Drugs
Figure EMEA Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume (MT) by Type (2012-2022)
Figure EMEA Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume Market Share by Type (Product Category) in 2016
Figure Alpha-blocker Product Picture
Figure Phosphodiesterase type-5 inhibitors Product Picture
Figure 5-alpha-Reductase inhibitors Product Picture
Figure EMEA Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume (MT) by Application (2012-2022)
Figure EMEA Sales Market Share of Benign Prostatic Hyperplasia (BPH) Drugs by Application in 2016
Figure Clinical medicine Examples
Figure Scientific research Examples
Figure Others Examples
Figure EMEA Benign Prostatic Hyperplasia (BPH) Drugs Market Size (Million USD) by Region (2012-2022)
Figure Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Million USD) Status and Forecast by Countries
Figure Middle East Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure Middle East Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Million USD) Status and Forecast by Countries
Figure Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Million USD) Status and Forecast by Countries
Figure EMEA Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume and Growth Rate (2012-2022)
Figure EMEA Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure EMEA Benign Prostatic Hyperplasia (BPH) Drugs Market Major Players Product Sales Volume (MT) (2012-2017)
Table EMEA Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume (MT) of Major Players (2012-2017)
Table EMEA Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Players (2012-2017)
Figure 2016 Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Players
Figure 2017 Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Players
Figure EMEA Benign Prostatic Hyperplasia (BPH) Drugs Market Major Players Product Revenue (Million USD) (2012-2017)
Table EMEA Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Million USD) by Players (2012-2017)
Table EMEA Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Players (2012-2017)
Table 2016 EMEA Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Players
Table 2017 EMEA Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Players
Table EMEA Benign Prostatic Hyperplasia (BPH) Drugs Sale Price (USD/Kg) by Players (2012-2017)
Table EMEA Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT) and Market Share by Type (2012-2017)
Table EMEA Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Type (2012-2017)
Figure Sales Market Share of Benign Prostatic Hyperplasia (BPH) Drugs by Type (2012-2017)
Figure EMEA Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2012-2017)
Table EMEA Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Million USD) and Market Share by Type (2012-2017)
Table EMEA Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Type (2012-2017)
Figure Revenue Market Share of Benign Prostatic Hyperplasia (BPH) Drugs by Type in 2016
Table EMEA Benign Prostatic Hyperplasia (BPH) Drugs Sale Price (USD/Kg) by Type (2012-2017)
Table EMEA Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT) and Market Share by Application (2012-2017)
Table EMEA Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Application (2012-2017)
Figure Sales Market Share of Benign Prostatic Hyperplasia (BPH) Drugs by Application (2012-2017)
Figure EMEA Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application in 2016
Table EMEA Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT) and Market Share by Region (2012-2017)
Table EMEA Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Region (2012-2017)
Figure Sales Market Share of Benign Prostatic Hyperplasia (BPH) Drugs by Region (2012-2017)
Figure EMEA Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in 2016
Table EMEA Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Million USD) and Market Share by Region (2012-2017)
Table EMEA Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Region (2012-2017)
Figure Revenue Market Share of Benign Prostatic Hyperplasia (BPH) Drugs by Region (2012-2017)
Figure EMEA Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share Regions in 2016
Table EMEA Benign Prostatic Hyperplasia (BPH) Drugs Sales Price (USD/Kg) by Region (2012-2017)
Figure Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT) and Growth Rate (2012-2017)
Figure Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Growth Rate (2012-2017)
Table Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT) by Type (2012-2017)
Table Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Type (2012-2017)
Figure Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Type in 2016
Table Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT) by Application (2012-2017)
Table Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Application (2012-2017)
Figure Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Application in 2016
Table Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT) by Countries (2012-2017)
Table Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Countries (2012-2017)
Figure Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Countries (2012-2017)
Figure Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Countries in 2016
Table Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Million USD) by Countries (2012-2017)
Table Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Countries (2012-2017)
Figure Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Countries (2012-2017)
Figure Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Countries in 2016
Figure Germany Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT) and Growth Rate (2012-2017)
Figure France Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT) and Growth Rate (2012-2017)
Figure UK Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT) and Growth Rate (2012-2017)
Figure Russia Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT) and Growth Rate (2012-2017)
Figure Italy Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT) and Growth Rate (2012-2017)
Figure Benelux Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT) and Growth Rate (2012-2017)
Figure Middle East Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT) and Growth Rate (2012-2017)
Figure Middle East Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Million USD) and Growth Rate (2012-2017)
Table Middle East Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT) by Type (2012-2017)
Table Middle East Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Type (2012-2017)
Figure Middle East Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Type (2012-2017)
Table Middle East Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT) by Applications (2012-2017)
Table Middle East Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Applications (2012-2017)
Figure Middle East Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application in 2016
Table Middle East Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume (MT) by Countries (2012-2017)
Table Middle East Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume Market Share by Countries (2012-2017)
Figure Middle East Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume Market Share by Countries in 2016
Table Middle East Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Million USD) by Countries (2012-2017)
Table Middle East Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Countries (2012-2017)
Figure Middle East Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Countries (2012-2017)
Figure Middle East Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Countries in 2016
Figure Saudi Arabia Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT) and Growth Rate (2012-2017)
Figure Israel Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT) and Growth Rate (2012-2017)
Figure UAE Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT) and Growth Rate (2012-2017)
Figure Iran Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT) and Growth Rate (2012-2017)
Figure Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT) and Growth Rate (2012-2017)
Figure Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Million USD) and Growth Rate (2012-2017)
Table Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT) by Type (2012-2017)
Table Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2012-2017)
Figure Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2012-2017)
Figure Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type in 2016
Table Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT) by Application (2012-2017)
Table Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2012-2017)
Figure Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2012-2017)
Table Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume (MT) by Countries (2012-2017)
Table Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Countries (2012-2017)
Figure Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Countries (2012-2017)
Figure Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Countries in 2016
Table Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Million USD) by Countries (2012-2017)
Table Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Countries (2012-2017)
Figure Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Countries (2012-2017)
Figure Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Countries in 2016
Figure South Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT) and Growth Rate (2012-2017)
Figure Nigeria Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT) and Growth Rate (2012-2017)
Figure Egypt Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT) and Growth Rate (2012-2017)
Figure Algeria Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT) and Growth Rate (2012-2017)
Table Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Basic Information List
Table Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2012-2017)
Figure Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT) and Growth Rate (2012-2017)
Figure Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in EMEA (2012-2017)
Figure Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share in EMEA (2012-2017)
Table Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Basic Information List
Table Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2012-2017)
Figure Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT) and Growth Rate (2012-2017)
Figure Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in EMEA (2012-2017)
Figure Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share in EMEA (2012-2017)
Table GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Basic Information List
Table GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2012-2017)
Figure GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT) and Growth Rate (2012-2017)
Figure GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in EMEA (2012-2017)
Figure GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share in EMEA (2012-2017)
Table Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Basic Information List
Table Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2012-2017)
Figure Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT) and Growth Rate (2012-2017)
Figure Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in EMEA (2012-2017)
Figure Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share in EMEA (2012-2017)
Table ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Drugs Basic Information List
Table ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2012-2017)
Figure ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT) and Growth Rate (2012-2017)
Figure ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in EMEA (2012-2017)
Figure ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share in EMEA (2012-2017)
Table Advaxis Benign Prostatic Hyperplasia (BPH) Drugs Basic Information List
Table Advaxis Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2012-2017)
Figure Advaxis Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT) and Growth Rate (2012-2017)
Figure Advaxis Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in EMEA (2012-2017)
Figure Advaxis Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share in EMEA (2012-2017)
Table Agennix Benign Prostatic Hyperplasia (BPH) Drugs Basic Information List
Table Agennix Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2012-2017)
Figure Agennix Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT) and Growth Rate (2012-2017)
Figure Agennix Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in EMEA (2012-2017)
Figure Agennix Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share in EMEA (2012-2017)
Table ANI Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Basic Information List
Table ANI Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2012-2017)
Figure ANI Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT) and Growth Rate (2012-2017)
Figure ANI Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in EMEA (2012-2017)
Figure ANI Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share in EMEA (2012-2017)
Table BHR Pharma Benign Prostatic Hyperplasia (BPH) Drugs Basic Information List
Table BHR Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2012-2017)
Figure BHR Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT) and Growth Rate (2012-2017)
Figure BHR Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in EMEA (2012-2017)
Figure BHR Pharma Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share in EMEA (2012-2017)
Table Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Drugs Basic Information List
Table Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2012-2017)
Figure Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT) and Growth Rate (2012-2017)
Figure Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in EMEA (2012-2017)
Figure Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share in EMEA (2012-2017)
Table Boehringer Ingelheim Benign Prostatic Hyperplasia (BPH) Drugs Basic Information List
Table Dendreo Benign Prostatic Hyperplasia (BPH) Drugs Basic Information List
Table Endo Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Basic Information List
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Benign Prostatic Hyperplasia (BPH) Drugs
Figure Manufacturing Process Analysis of Benign Prostatic Hyperplasia (BPH) Drugs
Figure Benign Prostatic Hyperplasia (BPH) Drugs Industrial Chain Analysis
Table Raw Materials Sources of Benign Prostatic Hyperplasia (BPH) Drugs Major Manufacturers in 2016
Table Major Buyers of Benign Prostatic Hyperplasia (BPH) Drugs
Table Distributors/Traders List
Figure EMEA Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT) and Growth Rate Forecast (2017-2022)
Figure EMEA Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Growth Rate Forecast (2017-2022)
Figure EMEA Benign Prostatic Hyperplasia (BPH) Drugs Price (USD/Kg) and Trend Forecast (2017-2022)
Table EMEA Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT) Forecast by Region (2017-2022)
Figure EMEA Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share Forecast by Region (2017-2022)
Table EMEA Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Million USD) Forecast by Region (2017-2022)
Figure EMEA Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share Forecast by Region (2017-2022)
Table Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT) Forecast by Countries (2017-2022)
Figure Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share Forecast by Countries (2017-2022)
Table Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Million USD) Forecast by Countries (2017-2022)
Figure Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share Forecast by Countries (2017-2022)
Table Middle East Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT) Forecast by Countries (2017-2022)
Figure Middle East Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share Forecast by Countries (2017-2022)
Table Middle East Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Million USD) Forecast by Countries (2017-2022)
Figure Middle East Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share Forecast by Countries (2017-2022)
Table Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT) Forecast by Countries (2017-2022)
Figure Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share Forecast by Countries (2017-2022)
Table Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue (Million USD) Forecast by Countries (2017-2022)
Figure Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share Forecast by Countries (2017-2022)
Table EMEA Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT) Forecast by Type (2017-2022)
Figure EMEA Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share Forecast by Type (2017-2022)
Table EMEA Benign Prostatic Hyperplasia (BPH) Drugs Sales (MT) Forecast by Application (2017-2022)
Figure EMEA Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share Forecast by Application (2017-2022)
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources

Global IgG Mediated Autoimmune Diseases Biologic Drugs Market (2024 Edition): Analysis By Antibody Source (Humanized, Fully Human, Chimeric, Other Sources), By Indication, By Region, By Country: Market Insights and Forecast (2019-2029)...

Executive Summary Azoth Analytics has released a research report titled "Global IgG Mediated Autoimmune Diseases Biologic Drugs Market (2024 Edition)" which provides a complete analysis of the Global IgG Mediated Autoimmune Diseases Biologic Drugs industry in terms of market segmentatio...

Europe Industrial Protective Clothing Market 2024...

Industrial protective clothing constitutes specialized attire fabricated from engineered textiles intended to safeguard personnel operating amid potentially perilous occupational environments from exposure to myriad hazards inherent to industrial settings such as manufacturing plants, construction s...

Africa Plant Protein Market 2023...

Plant protein refers to protein derived from plant-based sources such as legumes, grains, nuts, seeds, and certain vegetables. These proteins are valued for their nutritional benefits, as they are often rich in essential amino acids, fiber, vitamins, and minerals. Plant protein is widely used in veg...

Global Antibiotic Drugs Market (2024 Edition): Analysis By Drug Class (Cephalosporin, Penicillin, Macrolides, Fluoroquinolone, Others), Spectrum (Broad, Narrow), By Indication, By Region, By Country: Market Insights and Forecast (2019-2029)...

Executive Summary Azoth Analytics has released a research report titled "Global Antibiotic Drugs Market (2024 Edition)" which provides a complete analysis of the global Antibiotic Drugs industry in terms of market segmentation By Drug Class (Cephalosporin, Penicillin, Macrolides, Fluoro...

Europe Cutting Tools Market 2023-2033 by Tool Type (Solid Round, Indexable), Product (Groovers, Reamers, Milling Cutters, Drills), Material (Cemented Carbide, HSS, Ceramics, CBN), Chip Breaker (Step, Ridge, Universal, Separate), Application, Industry Vertical, Distribution Channel (Offline, Online), and Country: Trend Forecast and Growth Opportunity...

Europe cutting tools market was valued at $6.85 billion in 2023 and will grow by 4.6% annually over 2023-2033. The growth is driven by the increasing production and manufacturing activities, improved operational efficiency and innovative design, and an increasing demand for power tools for DIY activ...

Europe Paper Machine Clothing (PMC) Market 2023-2033 by Product Type (Forming Fabrics, Press Felts, Dryer Fabrics), Material (Nylon, Polyester, PVDF, Others), Application (Wrapping & Packaging Paper, Printing & Writing Paper, Household & Sanitary Paper, Newsprint, Others), and Country: Trend Forecast and Growth Opportunity...

Europe paper machine clothing (PMC) market was valued at $ 631.1 million in 2023 and will grow by 3.6% annually over 2023-2033. The growth is driven by the increasing demand for paper and paper-based products across various industries, technological advancements in the papermaking process, the intro...

Europe Endoscopy Devices Market 2023-2033 by Device Type, Hygiene, Application, End User, and Country: Trend Forecast and Growth Opportunity...

Europe endoscopy devices market was valued at $10.1 billion in 2023 and will grow by 5.9% annually over 2023-2033. The growth is driven by the increasing prevalence of chronic diseases, the growing demand for less invasive procedures, a rising adoption of disposable endoscopic components, growing ge...

Europe Digital Health and Wellness Market 2023-2033 by Product (Hardware, Solutions), Category (Health, Wellness), Connectivity (Cellular, NFC, Bluetooth, Wi-Fi), End User (Hospitals & Clinics, ASCs, Homecare & Individuals), Age Group (Pediatric, Adults, Geriatric), Distribution Channel (Online, Specialty Stores, Department Stores, Hypermarket), and Country: Trend Forecast and Growth Opportunity...

Europe digital health and wellness market was valued at $100.9 billion in 2023 and will grow by 18.9% annually over 2023-2033. The growth is driven by an increasing number of chronic diseases, the growing investment in health and wellness programs, the increased use of smartphones and wearable devic...

Europe Connected Healthcare Device Market 2023-2033 by Product (Medical Devices, Wellness Devices, Software & Services), Device Type (Wearable, Implantable, Stationary), Application (Remote Monitoring, Consultation and Diagnosis, Treatment, Fitness and Wellness), End User (Hospitals, Clinics, ASCs, Home Care), and Country: Trend Forecast and Growth Opportunity...

Europe connected healthcare device market was valued at $16 billion in 2023 and will grow by 19.2% annually over 2023-2033. The growth is driven by the emergence of telehealth and telemedicine services, benefits such as reliability and effective patient monitoring, the penetration of mobile and inte...

Europe Bioprocess Technology Market 2023-2033 by Product (Instruments, Consumables and Accessories), Process (Upstream, Downstream), Procedure, Application (Recombinant Proteins, Antibiotics, Biosimilars, mAbs, Others), End User (Biopharma Companies, CMOs, Institutes, CROs), and Country: Trend Forecast and Growth Opportunity...

Europe bioprocess technology market was valued at $6.56 billion in 2023 and will grow by 13.7% annually over 2023-2033. The growth is driven an increasing prevalence of chronic diseases, the widespread use of bioprocess technology, rising expenditures on R&D in the biotechnology sector, ongoing tech...